Role of estrogen treatment in the management of schizophrenia

CNS Drugs

Volumn 26, Issue 7, 2012, Pages 549-557

  Kulkarni, Jayashri ^a   Gavrilidis, Emmy ^a   Worsley, Roisin ^a   Hayes, Emily ^a  

^a Monash University Faculty of Medicine Nursing and Health Sciences Central Clinical School ^*  (Australia)

Author keywords

Estrogen; Men; Raloxifene; Schizophrenia; Women

Indexed keywords

CLOZAPINE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ESTROGEN THERAPY; FEMINIZATION; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS CANCER;

ANIMALS; ESTROGENS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX FACTORS;

EID: 84862536596     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11630660-000000000-00000     Document Type: Review

References (89)

1. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003 Apr; 28 Suppl. 2: 17-54 (Pubitemid 36335819)
2. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997 Mar; 42 (2): 139-51
3. Castle DJ, Wessely S, Murray RM. Sex and schizophrenia: effects of diagnostic stringency, and associations with and premorbid variables. Br J Psychiatry 1993 May; 162: 658-64 (Pubitemid 23150999)
4. Cotton SM, Lambert M, Schimmelmann BG, et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009 Oct; 114 (1-3): 17-24
5. Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust N Z J Psychiatry 2008 Jan; 42 (1): 74-82 (Pubitemid 350226665)
6. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76
7. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987 May; 150: 662-73 (Pubitemid 17061231)
8. Riecher-Rossler A, Seeman MV. Oestrogens and schizophrenia: introduction. Arch Womens Ment Health 2002 Nov; 5 (3): 91-2
9. Seeman MV. Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand 1986 Jun; 73 (6): 609-17 (Pubitemid 16100680)
10. Seeman MV. Psychopathology in women and men: focus on female hormones.AmJ Psychiatry 1997Dec; 154 (12): 1641-7 (Pubitemid 27516578)
11. Bergemann N, Parzer P, Runnebaum B, et al. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 2007 Apr 24; 37 (10): 1427-36 (Pubitemid 47581417)
12. Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med 2001 Sep-Oct; 63 (5): 822-9
13. Ko YH, Joe SH, Cho W, et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 2006; 53 (4): 169-75 (Pubitemid 44252776)
14. Rubin LH, Carter CS, Drogos L, et al. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 2010 Dec; 124 (1-3): 13-21
15. Gattaz WF, Vogel P, Riecher-Rossler A, et al. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 1994 Jul 15; 36 (2): 137-9 (Pubitemid 24227269)
16. Chang SS, Renshaw DC. Psychosis and pregnancy. Compr Ther 1986 Oct; 12 (10): 36-41 (Pubitemid 17210833)
17. Riecher-Rossler A, Hafner H. Schizophrenia and oestrogens: is there an association? Eur Arch Psychiatry Clin Neurosci 1993; 242 (6): 323-8
18. Fink G, Sumner BE, Rosie R, et al. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996 Jun; 16 (3): 325-44 (Pubitemid 26231262)
19. Hughes ZA, Liu F, Marquis K, et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for cns disorders. Curr Mol Pharmacol 2009 Nov; 2 (3): 215-36
20. ter Horst GJ. Estrogen in the limbic system. Vitam Horm 2010; 82: 319-38
21. McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001 Dec; 91 (6): 2785-801 (Pubitemid 33108046)
22. Cosimo Melcangi R, Garcia-Segura LM. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. Horm Behav 2010 Jan; 57 (1): 2-11
23. Taylor GT, Maloney S, Dearborn J, et al. Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology. Cent Nerv Syst Agents Med Chem 2009 Dec; 9 (4): 331-60
24. Gonzalez-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008 Mar 6; 452 (7183): 93-7 (Pubitemid 351355090)
25. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20 (5): 389-409 (Pubitemid 43763739)
26. Sanchez MG, Bourque M, Morissette M, et al. Steroidsdopamine interactions in the pathophysiology and treatment of cns disorders. CNS Neurosci Ther 2010 Jun; 16 (3): e43-71
27. Chavez C, Hollaus M, Scarr E, et al. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010 Mar 19; 1321: 51-9
28. Lokuge S, Frey BN, Foster JA, et al. The rapid effects of estrogen: a mini-review. Behav Pharmacol 2010 Sep; 21 (5-6): 465-72
29. Adams MM, Fink SE, Janssen WG, et al. Estrogen modulates synaptic N-methyl-D-aspartate receptor subunit distribution in the aged hippocampus. J Comp Neurol 2004 Jun 28; 474 (3): 419-26 (Pubitemid 38720435)
30. Bubenikova-Valesova V, Horacek J, Vrajova M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008 Jul; 32 (5): 1014-23 (Pubitemid 351756510)
31. 7 receptors. J Pharmacol Exp Ther 2010 Apr; 333 (1): 218-27
32. Gogos A, Kwek P, van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl). Epub 2011 Jul 29
33. Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17β-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology 2010 Jun; 35 (7): 1570-82
34. Arad M, Weiner I. Sex-dependent antipsychotic capacity of 17b-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology 2010Oct; 35 (11): 2179-92
35. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 2007 Dec; 27 (6): 604-8 (Pubitemid 350045668)
36. Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001 Apr 15; 49 (1-2): 1-52 (Pubitemid 32451739)
37. Fornito A, Yucel M, Pantelis C. Reconciling neuroimaging and neuropathological findings in schizophrenia and bipolar disorder. Curr Opin Psychiatry 2009 May; 22 (3): 312-9
38. Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr Clin North Am 2004 Mar; 27 (1): 1-18, vii (Pubitemid 38367767)
39. Arevalo MA, Santos-Galindo M, Bellini MJ, et al. Actions of estrogens on glial cells: Implications for neuroprotection. Biochim Biophys Acta 2010 Oct; 1800 (10): 1106-12
40. Arevalo MA, Santos-Galindo M, Lagunas N, et al. Selective estrogen receptor modulators as brain therapeutic agents. J Mol Endocrinol 2011 Feb; 46 (1): R1-9
41. Behl C. Estrogen can protect neurons: Modes of action. J Steroid Biochem Mol Biol 2003 Dec; 83 (1-5): 195-7
42. Bryant DN, Dorsa DM. Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity. Neuroscience 2010 Nov 10; 170 (4): 1261-9
43. Rao ML, Kolsch H. Effects of estrogen on brain development and neuroprotection: implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 2003 Apr; 28 Suppl. 2: 83-96 (Pubitemid 36332231)
44. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001 Jan; 63 (1): 29-60
45. Li J, Siegel M, Yuan M, et al. Estrogen enhances neurogenesis and behavioral recovery after stroke. J Cereb Blood Flow Metab 2011 Feb; 31 (2): 413-25
46. Liu M, Kelley MH, Herson PS, et al. Neuroprotection of sex steroids. Minerva Endocrinol 2010 Jun; 35 (2): 127-43
47. Yang LC, Zhang QG, Zhou CF, et al. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS One 2010; 5 (5): e9851
48. Kulkarni J, Riedel A, de Castella AR, et al. Estrogen: a potential treatment for schizophrenia. Schizophr Res 2001 Mar 1; 48 (1): 137-44
49. Kulkarni J, Riedel A, de Castella AR, et al. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch Womens Ment Health 2002 Nov; 5 (3): 99-104 (Pubitemid 35387787)
50. Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003 Sep; 27 (6): 1007-12 (Pubitemid 37141389)
51. Korhonen S, Saarijarvi S, Aito M. Successful estradiol treatment of psychotic symptoms in the premenstrual phase: a case report. Acta Psychiatr Scand 1995 Sep; 92 (3): 237-8
52. Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992 May; 149 (5): 587-95
53. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008 Aug; 65 (8): 955-60
54. Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane Database Syst Rev 2005 (4): CD004719
55. Mortimer AM. Relationship between estrogen and schizophrenia. Expert Rev Neurother 2007 Jan; 7 (1): 45-55 (Pubitemid 46105295)
56. Bergemann N, Mundt C, Parzer P, et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res 2005 May 1; 74 (2-3): 125-34 (Pubitemid 40255071)
57. Glazer WM, Naftolin F, Morgenstern H, et al. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 1985; 10 (3): 345-50 (Pubitemid 16237743)
58. Good KP, Kopala LC, Martzke JS, et al. Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr Res 1999; 12 (3): 131
59. Louza MR, Marques AP, Elkis H, et al. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res 2004 Feb 1; 66 (2-3): 97-100 (Pubitemid 38041107)
60. Markham JA. Sex steroids and schizophrenia. Rev Endocr Metab Disord. Epub 2011 May 21
61. Riecher-Rossler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci 2011; 8: 155-71
62. Hall KA, Keks NA, O'Connor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr 2005 Jun; 17 (2): 165-78 (Pubitemid 41073163)
63. Kirschbaum C, Schommer N, Federenko I, et al. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. J Clin Endocrinol Metab 1996 Oct; 81 (10): 3639-43 (Pubitemid 26339930)
64. Kyomen HH, Hennen J, Gottlieb GL, et al. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am J Psychiatry 2002 Jul; 159 (7): 1225-7 (Pubitemid 34743265)
65. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000 Mar; 55 (3): 328-33
66. Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. Am J Geriatr Psychiatry 1999; 7 (4): 339-48 (Pubitemid 29468663)
67. Arnold SE. Estrogen for refractory aggression after traumatic brain injury. Am J Psychiatry 1993; 150 (10): 1564-5 (Pubitemid 23289327)
68. Kulkarni J, de Castella A, Headey B, et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011 Feb; 125 (2-3): 278-83
69. DonCarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology 2009 Dec; 34 Suppl. 1: S113-22
70. Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for cns protection. CNS Drug Rev 2002 Fall; 8 (3): 309-30 (Pubitemid 35191288)
71. Cyr M, Calon F, Morissette M, et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des 2000 Aug; 6 (12): 1287-312 (Pubitemid 30604736)
72. Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002 Oct; 76 (4): 214-22 (Pubitemid 36151491)
73. Bryant HU. Selective estrogen receptor modulators. Rev Endocr Metab Disord 2002 Sep; 3 (3): 231-41
74. Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010 Sep; 35 (8): 1142-7
75. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011 Nov; 72 (11): 1552-7
76. Kretschmer E. Körperbau und charakter. Untersuchungen zum konstitutionsproblem und zur lehre von den temperamenten. Berlin: Springer, 1921
77. Riecher-Rossler A, Hafner H, Stumbaum M, et al. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20 (1): 203-14 (Pubitemid 24071103)
78. Maric N, Popovic V, Jasovic-Gasic M, et al. Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res 2005 Mar 1; 73 (2-3): 351-5 (Pubitemid 40093899)
79. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005 Dec; 150 (6): 1115-21 (Pubitemid 41773510)
80. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003 Oct 1; 290 (13): 1729-38 (Pubitemid 37430623)
81. Baker L, Meldrum KK, Wang M, et al. The role of estrogen in cardiovascular disease. J Surg Res 2003 Dec; 115 (2): 325-44 (Pubitemid 38021925)
82. Subbiah MT. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 1998 Jan; 217 (1): 23-9
83. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2001 Apr; 51 (4): 317-24 (Pubitemid 32391486)
84. Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast tissue. J Mammary Gland Biol Neoplasia 1997 Jan; 2 (1): 59-68 (Pubitemid 127717413)
85. Kulkarni J. Special issues in managing long-term mental illness in women. Int Rev Psychiatry 2010; 22 (2): 183-90
86. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288 (3): 321-33 (Pubitemid 34761611)
87. Beral V. Breast cancer and hormone-replacement therapy in the Million Women study. Lancet 2003 Aug 9; 362 (9382): 419-27 (Pubitemid 36999703)
88. Bergemann N, Parzer P, Jaggy S, et al. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr Bull 2008 Nov; 34 (6): 1172-81
89. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004 Jul; 65 (7): 932-9